Interleukin-17 and type 17 helper T cells in cancer management and research.
Interleukin-17 and type 17 helper T cells in cancer management and research.
复制标题
癌症管理和研究中的白介素17和17型辅助T细胞。
DOI：
10.2147/itt.s56529
复制
发表时间：
2014
影响因子：
7.2
通讯作者：
Housseau F
中科院分区：
文献类型：
--
作者：
Llosa NJ;Geis AL;Thiele Orberg E;Housseau F
自最近发现以来，辅助性 T 17 (Th17) 细胞在许多恶性肿瘤的肿瘤微环境中经常被检测到，但其临床意义仍然很大程度上未知。白介素 17 (IL-17) 检测通常与结直肠癌的不良预后相关，但它的存在与卵巢癌的抗肿瘤反应相关。许多实验模型说明了 Th17 细胞在肿瘤免疫中的不同作用，这似乎主要取决于肿瘤背景（癌症的类型、位置和阶段）。人们认识到IL-17由多种细胞类型产生，并且Th17细胞被赋予独特的功能可塑性。因此，当试图阐明潜在的免疫生物标志物和免疫靶标时，明确区分针对 Th17 的策略与其标志性细胞因子 IL-17 之间的关系极其重要。在这篇综述中，我们将总结有关人类癌症中 IL-17 和 Th17 检测的数据，考虑它们各自在抗肿瘤活性中作用的实验证据，并讨论 IL-17 作为治疗干预免疫靶点的潜力。
Since their recent discovery, T helper 17 (Th17) cells have been frequently detected in the tumor microenvironment of many malignancies, but their clinical implications remain largely unknown. Interleukin-17 (IL-17) detection is commonly related with poor outcomes in colorectal cancers, yet its presence is associated with antitumor responses in ovarian carcinomas. Numerous experimental models illustrate the divergent roles of Th17 cells in tumor immunity, which appears to be mainly dependent on the tumor context (type, location, and stage of cancer). It is recognized that IL-17 is produced by a variety of cell types and that Th17 cells are endowed with a unique functional plasticity. Therefore, when trying to elucidate potential immune biomarkers and immunotargets, it is extremely important to make a clear dissociation between strategies targeting Th17 versus its hallmark cytokine, IL-17. In this review, we will summarize the data regarding the detection of IL-17 and Th17 in human cancers, consider the experimental evidence on their respective roles in antitumor activity, and discuss the potential of IL-17 as an immune target for therapeutic interventions.